Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

A phase 1b clinical trial to determine the safety, tolerability and immunogenicity of simian adenovirus and poxvirus vectored vaccines against a Mycobacterium avium complex subspecies in patients with active Crohn's disease.

Sanderson J. et al, (2025), EBioMedicine, 113

Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.

Venkatraman N. et al, (2025), Lancet Microbe, 6

R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection study.

Venkatraman N. et al, (2025), Lancet Microbe, 6

The anti-circumsporozoite antibody response to repeated, seasonal booster doses of the malaria vaccine RTS,S/AS01E.

Ali MS. et al, (2025), NPJ Vaccines, 10

Validation of a multiplexed immunoassay for immunological analysis of pre erythrocytic malaria vaccines.

Stockdale LK. et al, (2025), NPJ Vaccines, 10

Dataset for Cytomegalovirus infection is a risk factor for TB disease but not TB infection

Stockdale L., (2024)

Validation of a multiplexed immunoassay for use in vaccine clinical trials and immunology studies of pre-erythrocytic malaria

Stockdale L. et al, (2024)

The Future of Vaccines for Tuberculosis.

Stockdale L. and Fletcher H., (2019), Clin Chest Med, 40, 849 - 856

OPTIMISATION OF A HUMAN BCG CHALLENGE MODEL

Wilkie MEM. et al, (2015), THORAX, 70, A27 - A27

Include forthcoming?